Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2011 (2011), Article ID 352580, 11 pages
http://dx.doi.org/10.1155/2011/352580
Review Article

Factors Affecting EWS-FLI1 Activity in Ewing's Sarcoma

Children's Cancer Research Institute, St Anna Kinderkrebsforschung, 1090 Vienna, Austria

Received 15 July 2011; Revised 31 August 2011; Accepted 31 August 2011

Academic Editor: Alessandro Gronchi

Copyright © 2011 David Herrero-Martin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. O. Delattre, J. Zucman, B. Plougastel et al., “Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours,” Nature, vol. 359, no. 6391, pp. 162–165, 1992. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. H. Kovar, “Downstream EWS/FLI1—upstream Ewing's sarcoma,” Genome Medicine, vol. 2, no. 1, article 8, 2010. View at Publisher · View at Google Scholar · View at PubMed
  3. C. Mackintosh, J. Madoz-Gúrpide, J. L. Ordóñez, D. Osuna, and D. Herrero-Martín, “The molecular pathogenesis of Ewing's sarcoma,” Cancer Biology and Therapy, vol. 9, no. 9, pp. 653–665, 2010. View at Google Scholar · View at Scopus
  4. N. Riggi, M. L. Suvà, D. Suvà et al., “EWS-FLI-1 expression triggers a ewing's sarcoma initiation program in primary human mesenchymal stem cells,” Cancer Research, vol. 68, no. 7, pp. 2176–2185, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  5. N. Riggi, M.-L. Suvà, and I. Stamenkovic, “The cancer stem cell paradigm in Ewing's sarcoma: what can we learn about these rare cells from a rare tumor?” Expert Review of Anticancer Therapy, vol. 11, no. 2, pp. 143–145, 2011. View at Publisher · View at Google Scholar · View at PubMed
  6. C. von Levetzow, X. Jiang, Y. Gwye et al., “Modeling initiation of ewing sarcoma in human neural crest cells,” PLoS One, vol. 6, no. 4, Article ID e19305, 2011. View at Publisher · View at Google Scholar · View at PubMed
  7. J. D. Hancock and S. L. Lessnick, “A transcriptional profiling meta-analysis reveals a core EWS-FLI gene expression signature,” Cell Cycle, vol. 7, no. 2, pp. 250–256, 2008. View at Google Scholar · View at Scopus
  8. M. Kauer, J. Ban, R. Kofler et al., “A molecular function map of Ewing's sarcoma,” PLoS One, vol. 4, no. 4, Article ID e5415, 2009. View at Publisher · View at Google Scholar · View at PubMed
  9. R. J. Olsen and S. H. Hinrichs, “Phosphorylation of the EWS IQ domain regulates transcriptional activity of the EWS/ATF1 and EWS/FLI1 fusion proteins,” Oncogene, vol. 20, no. 14, pp. 1756–1764, 2001. View at Publisher · View at Google Scholar · View at PubMed
  10. J. C. Deloulme, L. Prichard, O. Delattre, and D. R. Storm, “The prooncoprotein EWS binds calmodulin and is phosphorylated by protein kinase C through an IQ domain,” The Journal of Biological Chemistry, vol. 272, no. 43, pp. 27369–27377, 1997. View at Publisher · View at Google Scholar
  11. I. V. Klevernic, S. Morton, R. J. Davis, and P. Cohen, “Phosphorylation of Ewing's sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage,” Biochemical Journal, vol. 418, no. 3, pp. 625–634, 2009. View at Publisher · View at Google Scholar · View at PubMed
  12. R. Bachmaier, D. N. T. Aryee, G. Jug et al., “O-GlcNAcylation is involved in the transcriptional activity of EWS-FLI1 in Ewing's sarcoma,” Oncogene, vol. 28, no. 9, pp. 1280–1284, 2009. View at Publisher · View at Google Scholar · View at PubMed
  13. M. Wang, Y. Xie, L. Girnita et al., “Regulatory role of mevalonate and N-linked glycosylation in proliferation and expression of the EWS/FLI-1 fusion protein in Ewing's sarcoma cells,” Experimental Cell Research, vol. 246, no. 1, pp. 38–46, 1999. View at Publisher · View at Google Scholar · View at PubMed
  14. L. Girnita, M. Wang, Y. Xie et al., “Inhibition of N-linked glycosylation down-regulates insulin-like growth factor-1 receptor at the cell surface and kills Ewing's sarcoma cells: therapeutic implications,” Anti-Cancer Drug Design, vol. 15, no. 1, pp. 67–72, 2000. View at Google Scholar
  15. L. Yang, H. A. Chansky, and D. D. Hickstein, “EWS·Fli-1 fusion protein interacts with hyperphosphorylated RNA polymerase II and interferes with serine-arginine protein-mediated RNA splicing,” The Journal of Biological Chemistry, vol. 275, no. 48, pp. 37612–37618, 2000. View at Publisher · View at Google Scholar · View at PubMed
  16. R. Petermann, B. M. Mossier, D. N. T. Aryee, V. Khazak, E. A. Golemis, and H. Kovar, “Oncogenic EWS-Fli1 interacts with hsRPB7, a subunit of human RNA polymerase II,” Oncogene, vol. 17, no. 5, pp. 603–610, 1998. View at Google Scholar
  17. R. Todorova, “In vitro interaction between the N-terminus of the Ewing's sarcoma protein and the subunit of RNA polymerase II hsRPB7,” Molecular Biology Reports, vol. 36, no. 6, pp. 1269–1274, 2009. View at Publisher · View at Google Scholar · View at PubMed
  18. H. Zhou and K. A. W. Lee, “An hsRPB4/7-dependent yeast assay for trans-activation by the EWS oncogene,” Oncogene, vol. 20, no. 12, pp. 1519–1524, 2001. View at Publisher · View at Google Scholar · View at PubMed
  19. R. Ramakrishnan, Y. Fujimura, J. P. Zou et al., “Role of protein-protein interactions in the antiapoptotic function of EWS-Fli-1,” Oncogene, vol. 23, no. 42, pp. 7087–7094, 2004. View at Publisher · View at Google Scholar · View at PubMed
  20. L. Spahn, C. Siligan, R. Bachmaier, J. A. Schmid, D. N. T. Aryee, and H. Kovar, “Homotypic and heterotypic interactions of EWS, FLI1 and their oncogenic fusion protein,” Oncogene, vol. 22, no. 44, pp. 6819–6829, 2003. View at Publisher · View at Google Scholar · View at PubMed
  21. S. Pahlich, L. Quero, B. Roschitzki, R. P. Leemann-Zakaryan, and H. Gehring, “Analysis of Ewing sarcoma (EWS)-binding proteins: interaction with hnRNP M, U, and RNA-helicases p68/72 within protein-RNA complexes,” Journal of Proteome Research, vol. 8, no. 10, pp. 4455–4465, 2009. View at Publisher · View at Google Scholar · View at PubMed
  22. J. A. Toretsky, V. Erkizan, A. Levenson et al., “Oncoprotein EWS-FLI1 activity is enhanced by RNA helicase A,” Cancer Research, vol. 66, no. 11, pp. 5574–5581, 2006. View at Publisher · View at Google Scholar · View at PubMed
  23. L. Spahn, R. Petermann, C. Siligan, J. A. Schmid, D. N. T. Aryee, and H. Kovar, “Interaction of the EWS NH2 terminus with BARD1 links the Ewing's sarcoma gene to a common tumor suppressor pathway,” Cancer Research, vol. 62, no. 16, pp. 4583–4587, 2002. View at Google Scholar
  24. S. Kim, C. T. Denny, and R. Wisdom, “Cooperative DNA binding with AP-1 proteins is required for transformation by EWS-Ets fusion proteins,” Molecular and Cellular Biology, vol. 26, no. 7, pp. 2467–2478, 2006. View at Publisher · View at Google Scholar · View at PubMed
  25. M. Kinsey, R. Smith, A. K. Iyer, E. R. B. McCabe, and S. L. Lessnick, “EWS/FLI and its downstream target NR0B1 interact directly to modulate transcription and oncogenesis in Ewing's sarcoma,” Cancer Research, vol. 69, no. 23, pp. 9047–9055, 2009. View at Publisher · View at Google Scholar · View at PubMed
  26. L. L. Knoop and S. J. Baker, “EWS/FLI alters 5′-splice site selection,” The Journal of Biological Chemistry, vol. 276, no. 25, pp. 22317–22322, 2001. View at Publisher · View at Google Scholar · View at PubMed
  27. B. Deneen and C. T. Denny, “Loss of p16 pathways stabilizes EWS/FLI1 expression and complements EWS/FLI1 mediated transformation,” Oncogene, vol. 20, no. 46, pp. 6731–6741, 2001. View at Publisher · View at Google Scholar · View at PubMed
  28. S. L. Lessnick, C. S. Dacwag, and T. R. Golub, “The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts,” Cancer Cell, vol. 1, no. 4, pp. 393–401, 2002. View at Publisher · View at Google Scholar
  29. P. P. Lin, M. K. Pandey, F. Jin et al., “EWS-FLI1 induces developmental abnormalities and accelerates sarcoma formation in a transgenic mouse model,” Cancer Research, vol. 68, no. 21, pp. 8968–8975, 2008. View at Publisher · View at Google Scholar · View at PubMed
  30. H. Kovar, G. Jug, D. N. T. Aryee et al., “Among genes involved in the RB dependent cell cycle regulatory cascade, the p16 tumor suppressor gene is frequently lost in the Ewing family of tumors,” Oncogene, vol. 15, no. 18, pp. 2225–2232, 1997. View at Google Scholar
  31. J. A. López-Guerrero, A. Pellín, R. Noguera, C. Carda, and A. Llombart-Bosch, “Molecular analysis of the 9p21 locus and p53 genes in Ewing family tumors,” Laboratory Investigation, vol. 81, no. 6, pp. 803–814, 2001. View at Google Scholar
  32. E. De Alava, C. R. Antonescu, A. Panizo et al., “Prognostic impact of P53 status in Ewing sarcoma,” Cancer, vol. 89, no. 4, pp. 783–792, 2000. View at Publisher · View at Google Scholar
  33. J. Ban, I. M. Bennani-Baiti, M. Kauer et al., “EWS-FLI1 suppresses NOTCH-activated p53 in Ewing's sarcoma,” Cancer Research, vol. 68, no. 17, pp. 7100–7109, 2008. View at Publisher · View at Google Scholar · View at PubMed
  34. S. Batra, C. P. Reynolds, and B. J. Maurer, “Fenretinide cytotoxicity for Ewing's sarcoma and primitive neuroectodermal tumor cell lines is decreased by hypoxia and synergistically enhanced by ceramide modulators,” Cancer Research, vol. 64, no. 15, pp. 5415–5424, 2004. View at Publisher · View at Google Scholar · View at PubMed
  35. D. W. J. Van Der Schaft, F. Hillen, P. Pauwels et al., “Tumor cell plasticity in Ewing sarcoma, an alternative circulatory system stimulated by hypoxia,” Cancer Research, vol. 65, no. 24, pp. 11520–11528, 2005. View at Publisher · View at Google Scholar · View at PubMed
  36. D. N. T. Aryee, S. Niedan, M. Kauer et al., “Hypoxia modulates EWS-FLI1 transcriptional signature and enhances the malignant properties of Ewing's Sarcoma cells In vitro,” Cancer Research, vol. 70, no. 10, pp. 4015–4023, 2010. View at Publisher · View at Google Scholar · View at PubMed
  37. H. J. Knowles, K. L. Schaefer, U. Dirksen, and N. A. Athanasou, “Hypoxia and hypoglycaemia in Ewing's sarcoma and osteosarcoma: regulation and phenotypic effects of Hypoxia-Inducible Factor,” BMC Cancer, vol. 10, article 372, 2010. View at Publisher · View at Google Scholar · View at PubMed
  38. D. Yee, R. E. Favoni, G. S. Lebovic et al., “Insulin-like growth factor I expression by tumors of neuroectodermal origin with the t(11;22) chromosomal translocation. A potential autocrine growth factor,” The Journal of Clinical Investigation, vol. 86, no. 6, pp. 1806–1814, 1990. View at Google Scholar
  39. K. Scotlandi, M. C. Manara, M. Serra et al., “Expression of insulin-like growth factor system components in Ewing's sarcoma and their association with survival,” European Journal of Cancer, vol. 47, no. 8, pp. 1258–1266, 2011. View at Google Scholar
  40. S. E. Steigen, D. F. Schaeffer, R. B. West, and T. O. Nielsen, “Expression of insulin-like growth factor 2 in mesenchymal neoplasms,” Modern Pathology, vol. 22, no. 7, pp. 914–921, 2009. View at Publisher · View at Google Scholar · View at PubMed
  41. J. A. Toretsky, T. Kalebic, V. Blakesley, D. LeRoith, and L. J. Helman, “The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts,” The Journal of Biological Chemistry, vol. 272, no. 49, pp. 30822–30827, 1997. View at Publisher · View at Google Scholar
  42. D. Herrero-Martín, D. Osuna, J. L. Ordó̃ez et al., “Stable interference of EWS-FLI1 in an Ewing sarcoma cell line impairs IGF-1/IGF-1R signalling and reveals TOPK as a new target,” British Journal of Cancer, vol. 101, no. 1, pp. 80–90, 2009. View at Publisher · View at Google Scholar · View at PubMed
  43. T. Baumuratova, D. Surdez, B. Delyon et al., “Localizing potentially active post-transcriptional regulations in the Ewing's sarcoma gene regulatory network,” BMC Systems Biology, vol. 4, article 146, 2010. View at Publisher · View at Google Scholar · View at PubMed
  44. L. Cironi, N. Riggi, P. Provero et al., “IGF1 is a common target gene of Ewing's sarcoma fusion proteins in mesenchymal progenitor cells,” PLoS One, vol. 3, no. 7, Article ID e2634, 2008. View at Publisher · View at Google Scholar · View at PubMed
  45. K. Scotlandi, S. Benini, M. Sarti et al., “Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target,” Cancer Research, vol. 56, no. 20, pp. 4570–4574, 1996. View at Google Scholar
  46. L. Girnita, A. Girnita, M. Wang, J. M. Meis-Kindblom, L. G. Kindblom, and O. Larsson, “A link between basic fibroblast growth factor (bFGF) and EWS/FLI-1 in Ewing's sarcoma cells,” Oncogene, vol. 19, no. 37, pp. 4298–4301, 2000. View at Google Scholar
  47. D. G. Fan, F. Zhao, Y. Ding et al., “BLCAP induces apoptosis in human Ewing's sarcoma cells,” Experimental Biology and Medicine, vol. 236, no. 9, pp. 1030–1035, 2011. View at Google Scholar
  48. J. Ban, G. Jug, P. Mestdagh et al., “Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma,” Oncogene, vol. 30, no. 18, pp. 2173–2180, 2011. View at Publisher · View at Google Scholar · View at PubMed
  49. N. Riggi, M. L. Suvà, C. De Vito et al., “EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells,” Genes and Development, vol. 24, no. 9, pp. 916–932, 2010. View at Publisher · View at Google Scholar · View at PubMed
  50. E. L. McKinsey, J. K. Parrish, A. E. Irwin et al., “A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs,” Oncogene. In press. View at Publisher · View at Google Scholar · View at PubMed
  51. C. De Vito, N. Riggi, M.-L. Suvà et al., “Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development,” PLoS One, vol. 6, no. 8, Article ID e23592, 2011. View at Google Scholar
  52. J. S. Kim, F. Pirnia, Y. H. Choi et al., “Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G1 checkpoint,” Oncogene, vol. 19, no. 52, pp. 6082–6090, 2000. View at Publisher · View at Google Scholar · View at PubMed
  53. H. V. Erkizan, Y. Kong, M. Merchant et al., “A small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing's sarcoma,” Nature Medicine, vol. 15, no. 7, pp. 750–756, 2009. View at Publisher · View at Google Scholar · View at PubMed
  54. K. Scotlandi, S. Benini, P. Nanni et al., “Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice,” Cancer Research, vol. 58, no. 18, pp. 4127–4131, 1998. View at Google Scholar
  55. R. Strammiello, S. Benini, M. C. Manara et al., “Impact of IGF-I/IGF-IR circuit on the angiogenetic properties of Ewing's sarcoma cells,” Hormone and Metabolic Research, vol. 35, no. 11-12, pp. 675–684, 2003. View at Publisher · View at Google Scholar · View at PubMed
  56. D. Olmos, S. Postel-Vinay, L. R. Molife et al., “Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study,” The Lancet Oncology, vol. 11, no. 2, pp. 129–135, 2010. View at Publisher · View at Google Scholar
  57. J. A. Toretsky and R. Gorlick, “IGF-1R targeted treatment of sarcoma,” The Lancet Oncology, vol. 11, no. 2, pp. 105–106, 2010. View at Publisher · View at Google Scholar
  58. R. Kurzrock, A. Patnaik, J. Aisner et al., “A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors,” Clinical Cancer Research, vol. 16, no. 8, pp. 2458–2465, 2010. View at Publisher · View at Google Scholar · View at PubMed
  59. A. Naing, R. Kurzrock, A. M. Burger et al., “Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer,” Clinical Cancer Research, vol. 17, no. 18, pp. 6052–6060, 2011. View at Google Scholar
  60. C. Garofalo, M. C. Manara, G. Nicoletti et al., “Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling,” Oncogene, vol. 30, no. 24, pp. 2730–2740, 2011. View at Google Scholar
  61. H. G. Kang, J. M. Jenabi, X. F. Liu, C. P. Reynolds, T. J. Triche, and P. H. B. Sorensen, “Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of ewing tumor cells,” Molecular Cancer Therapeutics, vol. 9, no. 5, pp. 1396–1407, 2010. View at Publisher · View at Google Scholar · View at PubMed
  62. P. J. Grohar, G. M. Woldemichael, L. B. Griffin et al., “Identification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screening,” Journal of the National Cancer Institute, vol. 103, no. 12, pp. 962–978, 2011. View at Google Scholar
  63. M. Djavaheri-Mergny, J. Wietzerbin, and F. Besançon, “2-Methoxyestradiol induces apoptosis in Ewing sarcoma cells through mitochondrial hydrogen peroxide production,” Oncogene, vol. 22, no. 17, pp. 2558–2567, 2003. View at Publisher · View at Google Scholar · View at PubMed
  64. S. Lorin, A. Borges, L. R. Dos Santos et al., “c-Jun NH2-terminal kinase activation is essential for DRAM-dependent induction of autophagyand apoptosis in 2-methoxyestradiol-treated ewing sarcoma cells,” Cancer Research, vol. 69, no. 17, pp. 6924–6931, 2009. View at Publisher · View at Google Scholar · View at PubMed
  65. G. Lu, V. Punj, and P. M. Chaudhary, “Proteasome inhibitor Bortezomib induces cell cycle arrest and apoptosis in cell lines derived from Ewing's sarcoma family of tumors and synergizes with TRAIL,” Cancer Biology and Therapy, vol. 7, no. 4, pp. 603–608, 2008. View at Google Scholar
  66. K. I. Pishas, F. Al-Ejeh, I. Zinonos et al., “Nutlin-3a is a potential therapeutic for Ewing sarcoma,” Clinical Cancer Research, vol. 17, no. 3, pp. 494–504, 2011. View at Publisher · View at Google Scholar · View at PubMed
  67. J. Sonnemann, C. D. Palani, S. Wittig et al., “Anticancer effects of the p53 activator nutlin-3 in Ewing's sarcoma cells,” European Journal of Cancer, vol. 47, no. 9, pp. 1432–1441, 2011. View at Publisher · View at Google Scholar · View at PubMed
  68. P. J. Grohar, L. B. Griffin, C. Yeung et al., “Ecteinascidin 743 interferes with the activity of EWS-FLI1 in ewing sarcoma cells,” Neoplasia, vol. 13, no. 2, pp. 145–153, 2011. View at Publisher · View at Google Scholar
  69. K. Stegmaier, J. S. Wong, K. N. Ross et al., “Signature-based small molecule screening identifies cytosine arabinoside as an EWS/FLI modulator in ewing sarcoma,” PLoS Medicine, vol. 4, no. 4, article e122, 2007. View at Publisher · View at Google Scholar · View at PubMed
  70. S. G. Dubois, M. D. Krailo, S. L. Lessnick et al., “Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory ewing sarcoma: a report from the children's oncology group,” Pediatric Blood and Cancer, vol. 52, no. 3, pp. 324–327, 2009. View at Publisher · View at Google Scholar · View at PubMed
  71. A. Uren and J. A. Toretsky, “Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent,” Future Oncology, vol. 1, no. 4, pp. 521–528, 2005. View at Publisher · View at Google Scholar · View at PubMed
  72. K. P. Ng, G. Potikyan, R. O. V. Savene, C. T. Denny, V. N. Uversky, and K. A. W. Lee, “Multiple aromatic side chains within a disordered structure are critical for transcription and transforming activity of EWS family oncoproteins,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 2, pp. 479–484, 2007. View at Publisher · View at Google Scholar · View at PubMed
  73. A. Arvand, S. M. Welford, M. A. Teitell, and C. T. Denny, “The cooh-terminal domain of FLI-1 is necessary for full tumorigenesis and transcriptional modulation by EWS/FLI-11,2,” Cancer Research, vol. 61, no. 13, pp. 5311–5317, 2001. View at Google Scholar
  74. S. M. Welford, S. P. Hebert, B. Deneen, A. Arvand, and C. T. Denny, “DNA binding domain-independent pathways are involved in EWS/FLI1-mediated oncogenesis,” The Journal of Biological Chemistry, vol. 276, no. 45, pp. 41977–41984, 2001. View at Publisher · View at Google Scholar · View at PubMed
  75. R. Li, H. Pei, and D. K. Watson, “Regulation of Ets function by protein—protein interactions,” Oncogene, vol. 19, no. 55, pp. 6514–6523, 2000. View at Publisher · View at Google Scholar · View at PubMed
  76. H. V. Erkizan, V. N. Uversky, and J. A. Toretsky, “Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma,” Clinical Cancer Research, vol. 16, no. 16, pp. 4077–4083, 2010. View at Publisher · View at Google Scholar · View at PubMed
  77. A. Varki, R. D. Cummings, J. D. Esko et al., Essentials of Glycobiology, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2nd edition, 2009.
  78. K. A. W. Lee, “Ewings family oncoproteins: drunk, disorderly and in search of partners,” Cell Research, vol. 17, no. 4, pp. 286–288, 2007. View at Publisher · View at Google Scholar · View at PubMed
  79. W. A. May, S. L. Lessnick, B. S. Braun et al., “The Ewing's sarcoma EWS/FLI-1 fusion gene encodes a more potent transcriptional activator and is a more powerful transforming gene than FLI- 1,” Molecular and Cellular Biology, vol. 13, no. 12, pp. 7393–7398, 1993. View at Google Scholar
  80. W. A. May, M. L. Gishizky, S. L. Lessnick et al., “Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 90, no. 12, pp. 5752–5756, 1993. View at Google Scholar
  81. S. L. Lessnick, B. S. Braun, C. T. Denny, and W. A. May, “Multiple domains mediate transformation by the Ewing's sarcoma EWS/FLI-1 fusion gene,” Oncogene, vol. 10, no. 3, pp. 423–431, 1995. View at Google Scholar
  82. F. Nakatani, K. Tanaka, R. Sakimura et al., “Identification of p21WAF1/CIP1 as a direct target of EWS-Fli1 oncogenic fusion protein,” The Journal of Biological Chemistry, vol. 278, no. 17, pp. 15105–15115, 2003. View at Publisher · View at Google Scholar · View at PubMed
  83. B. Fuchs, C. Y. Inwards, and R. Janknecht, “Upregulation of the matrix metalloproteinase-1 gene by the Ewing's sarcoma associated EWS-ER81 and EWS-Fli-1 oncoproteins, c-Jun and p300,” FEBS Letters, vol. 553, no. 1-2, pp. 104–108, 2003. View at Publisher · View at Google Scholar
  84. R. Smith, L. A. Owen, D. J. Trem et al., “Expression profiling of EWS/FLI identifies NKX2.2 as a critical target gene in Ewing's sarcoma,” Cancer Cell, vol. 9, no. 5, pp. 405–416, 2006. View at Publisher · View at Google Scholar · View at PubMed
  85. L. A. Owen, A. A. Kowalewski, and S. L. Lessnick, “EWS/FLI mediates transcriptional repression via NKX2.2 during oncogenic transformation in Ewing's sarcoma,” PLoS One, vol. 3, no. 4, Article ID e1965, 2008. View at Publisher · View at Google Scholar · View at PubMed
  86. L. L. Knoop and S. J. Baker, “The splicing factor U1C represses EWS/FLI-mediated transactivation,” The Journal of Biological Chemistry, vol. 275, no. 32, pp. 24865–24871, 2000. View at Publisher · View at Google Scholar · View at PubMed
  87. H. A. Chansky, M. Hu, D. D. Hickstein, and L. Yang, “Oncogenic TLS/ERG and EWS/Fli-1 fusion proteins inhibit RNA splicing mediated by YB-1 protein,” Cancer Research, vol. 61, no. 9, pp. 3586–3590, 2001. View at Google Scholar
  88. Y. Muto, D. P. Krummel, C. Oubridge et al., “The structure and biochemical properties of the human spliceosomal protein U1C,” Journal of Molecular Biology, vol. 341, no. 1, pp. 185–198, 2004. View at Publisher · View at Google Scholar · View at PubMed
  89. J. T. Zilfou and S. W. Lowe, “Tumor suppressive functions of p53,” Cold Spring Harbor Perspectives in Biology, vol. 1, no. 5, Article ID a001883, 2009. View at Publisher · View at Google Scholar · View at PubMed
  90. P. Ozenne, B. Eymin, E. Brambilla, and S. Gazzeri, “The ARF tumor suppressor: structure, functions and status in cancer,” International Journal of Cancer, vol. 127, no. 10, pp. 2239–2247, 2010. View at Publisher · View at Google Scholar · View at PubMed
  91. Q. Lin, X. Cong, and Z. Yun, “Differential hypoxic regulation of hypoxia-inducible factors 1α and 2α,” Molecular Cancer Research, vol. 9, no. 6, pp. 757–765, 2011. View at Publisher · View at Google Scholar · View at PubMed
  92. X. Lu and Y. Kang, “Hypoxia and hypoxia-inducible factors: master regulators of metastasis,” Clinical Cancer Research, vol. 16, no. 24, pp. 5928–5935, 2010. View at Publisher · View at Google Scholar · View at PubMed
  93. M. C. Brahimi-Horn, G. Bellot, and J. Pouysségur, “Hypoxia and energetic tumour metabolism,” Current Opinion in Genetics and Development, vol. 21, no. 1, pp. 67–72, 2010. View at Publisher · View at Google Scholar · View at PubMed
  94. K. M. A. Rouschop, T. Van Den Beucken, L. Dubois et al., “The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5,” The Journal of Clinical Investigation, vol. 120, no. 1, pp. 127–141, 2010. View at Publisher · View at Google Scholar · View at PubMed
  95. J. T. Erler, C. J. Cawthorne, K. J. Williams et al., “Hypoxia-mediated down-regulation of bid and bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance,” Molecular and Cellular Biology, vol. 24, no. 7, pp. 2875–2889, 2004. View at Publisher · View at Google Scholar
  96. P. Vaupel and A. Mayer, “Hypoxia in cancer: significance and impact on clinical outcome,” Cancer and Metastasis Reviews, vol. 26, no. 2, pp. 225–239, 2007. View at Publisher · View at Google Scholar · View at PubMed
  97. P. Francis, H. M. Namløs, C. Müller et al., “Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential,” BMC Genomics, vol. 8, article 73, 2007. View at Publisher · View at Google Scholar · View at PubMed
  98. K. Takenaga, “Angiogenic signaling aberrantly induced by tumor hypoxia,” Frontiers in Bioscience, vol. 16, no. 1, pp. 31–48, 2011. View at Publisher · View at Google Scholar
  99. M. Kilic, H. Kasperczyk, S. Fulda, and K. M. Debatin, “Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance,” Oncogene, vol. 26, no. 14, pp. 2027–2038, 2007. View at Publisher · View at Google Scholar · View at PubMed
  100. A. S. Martins, C. Mackintosh, D. Herrero Martín et al., “Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor,” Clinical Cancer Research, vol. 12, no. 11, pp. 3532–3540, 2006. View at Publisher · View at Google Scholar · View at PubMed
  101. R. Schickel, B. Boyerinas, S. M. Park, and M. E. Peter, “MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death,” Oncogene, vol. 27, no. 45, pp. 5959–5974, 2008. View at Publisher · View at Google Scholar · View at PubMed
  102. M. I. Almeida, R. M. Reis, and G. A. Calin, “MicroRNA history: discovery, recent applications, and next frontiers,” Mutation Research. In press. View at Publisher · View at Google Scholar · View at PubMed
  103. R. W. Carthew and E. J. Sontheimer, “Origins and mechanisms of miRNAs and siRNAs,” Cell, vol. 136, no. 4, pp. 642–655, 2009. View at Publisher · View at Google Scholar · View at PubMed
  104. B. N. Davis-Dusenbery and A. Hata, “MicroRNA in cancer: the involvement of aberrant microRNA biogenesis regulatory pathways,” Genes and Cancer, vol. 1, no. 11, pp. 1100–1114, 2011. View at Publisher · View at Google Scholar · View at PubMed
  105. T. A. Farazi, J. I. Spitzer, P. Morozov, and T. Tuschl, “MiRNAs in human cancer,” Journal of Pathology, vol. 223, no. 2, pp. 102–115, 2011. View at Publisher · View at Google Scholar · View at PubMed
  106. L. A. MacFarlane and P. R. Murphy, “MicroRNA: biogenesis, function and role in cancer,” Current Genomics, vol. 11, no. 7, pp. 537–561, 2010. View at Google Scholar
  107. J. S. Wei, P. Johansson, Q. R. Chen et al., “MicroRNA profiling identifies cancer-specific and prognostic signatures in pediatric malignancies,” Clinical Cancer Research, vol. 15, no. 17, pp. 5560–5568, 2009. View at Publisher · View at Google Scholar · View at PubMed
  108. S. Subramanian, W. O. Lui, C. H. Lee et al., “MicroRNA expression signature of human sarcomas,” Oncogene, vol. 27, no. 14, pp. 2015–2026, 2008. View at Publisher · View at Google Scholar · View at PubMed
  109. A. L. Sarver, R. Phalak, V. Thayanithy, and S. Subramanian, “S-MED: sarcoma microRNA expression database,” Laboratory Investigation, vol. 90, no. 5, pp. 753–761, 2010. View at Publisher · View at Google Scholar · View at PubMed
  110. J. Zhang, H. Guo, H. Zhang et al., “Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene friend leukemia virus integration 1 gene,” Cancer, vol. 117, no. 1, pp. 86–95, 2011. View at Publisher · View at Google Scholar · View at PubMed
  111. S. J. Kim, J. S. Oh, J. Y. Shin et al., “Development of microRNA-145 for therapeutic application in breast cancer,” Journal of Controlled Release, vol. 155, no. 3, pp. 427–434, 2011. View at Google Scholar
  112. S. Wach, M. Hart, E. Nolte, J. Szczyrba, B. Wullich, and F. Graesser, “The ERG 3'-UTR is a target of miR-145 and expression patterns of ERG isoforms are altered in prostate cancer,” in Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research (AACR '11), Orlando, Fla, USA, April 2011.
  113. P. C. Hollenhorst, L. P. McIntosh, and B. J. Graves, “Genomic and biochemical insights into the specificity of ETS transcription factors,” Annual Review of Biochemistry, vol. 80, pp. 437–471, 2011. View at Publisher · View at Google Scholar · View at PubMed
  114. V. Subbiah and P. Anderson, “Targeted therapy of Ewing's sarcoma,” Sarcoma, vol. 2011, Article ID 686985, 2011. View at Publisher · View at Google Scholar · View at PubMed
  115. K. Tanaka, T. Iwakuma, K. Harimaya, H. Sato, and Y. Iwamoto, “EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells,” The Journal of Clinical Investigation, vol. 99, no. 2, pp. 239–247, 1997. View at Google Scholar
  116. J. A. Toretsky, Y. Connell, L. Neckers, and N. K. Bhat, “Inhibition of EWS-FLI-1 fusion protein with antisense oligodeoxynucleotides,” Journal of Neuro-Oncology, vol. 31, no. 1-2, pp. 9–16, 1997. View at Google Scholar
  117. M. Ouchida, T. Ohno, Y. Fujimura, V. N. Rao, and E. S. P. Reddy, “Loss of tumorigenicity of Ewing's sarcoma cells expressing antisense RNA to EWS-fusion transcripts,” Oncogene, vol. 11, no. 6, pp. 1049–1054, 1995. View at Google Scholar
  118. H. Kovar, D. N. T. Aryee, G. Jug et al., “EWS/FLI-1 antagonists induce growth inhibition of Ewing tumor cells in vitro,” Cell Growth and Differentiation, vol. 7, no. 4, pp. 429–437, 1996. View at Google Scholar
  119. T. Dohjima, T. Ohno, Y. Banno, Y. Nozawa, Y. Wen-Yi, and K. Shimizu, “Preferential down-regulation of phospholipase C-β in Ewing's sarcoma cells transfected with antisense EWS-Fli-1,” British Journal of Cancer, vol. 82, no. 1, pp. 16–19, 2000. View at Google Scholar
  120. Y. Matsumoto, K. Tanaka, F. Nakatani, T. Matsunobu, S. Matsuda, and Y. Iwamoto, “Downregulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G1 regulatory genes,” British Journal of Cancer, vol. 84, no. 6, pp. 768–775, 2001. View at Publisher · View at Google Scholar · View at PubMed
  121. S. Asami, M. Chin, H. Shichino et al., “Treatment of Ewing's sarcoma using an antisense oligodeoxynucleotide to regulate the cell cycle,” Biological and Pharmaceutical Bulletin, vol. 31, no. 3, pp. 391–394, 2008. View at Publisher · View at Google Scholar
  122. A. Prieur, F. Tirode, P. Cohen, and O. Delattre, “EWS/FLI-1 silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3,” Molecular and Cellular Biology, vol. 24, no. 16, pp. 7275–7283, 2004. View at Publisher · View at Google Scholar · View at PubMed
  123. I. Takigami, T. Ohno, Y. Kitade et al., “Synthetic siRNA targeting the breakpoint of EWS/Fli-1 inhibits growth of Ewing sarcoma xenografts in a mouse model,” International Journal of Cancer, vol. 128, no. 1, pp. 216–226, 2011. View at Publisher · View at Google Scholar · View at PubMed
  124. T. Dohjima, N. S. Lee, H. Li, T. Ohno, and J. J. Rossi, “Small interfering RNAs expressed from a Pol III promoter suppress the EWS/Fli-1 transcript in an Ewing sarcoma cell line,” Molecular Therapy, vol. 7, no. 6, pp. 811–816, 2003. View at Publisher · View at Google Scholar
  125. H. A. Chansky, F. Barahmand-pour, Q. Mei et al., “Targeting of EWS/FLI-1 by RNA interference attenuates the tumor phenotype of Ewing's sarcoma cells in vitro,” Journal of Orthopaedic Research, vol. 22, no. 4, pp. 910–917, 2004. View at Publisher · View at Google Scholar · View at PubMed
  126. E. García-Aragoncillo, J. Carrillo, E. Lalli et al., “DAX1, a direct target of EWS/FLI1 oncoprotein, is a principal regulator of cell-cycle progression in Ewing's tumor cells,” Oncogene, vol. 27, no. 46, pp. 6034–6043, 2008. View at Publisher · View at Google Scholar · View at PubMed
  127. S. Nozawa, T. Ohno, Y. Banno et al., “Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells,” The Journal of Biological Chemistry, vol. 280, no. 30, pp. 27544–27551, 2005. View at Publisher · View at Google Scholar · View at PubMed
  128. J. Carrillo, E. García-Aragoncillo, D. Azorín et al., “Cholecystokinin down-regulation by RNA interference impairs Ewing tumor growth,” Clinical Cancer Research, vol. 13, no. 8, pp. 2429–2440, 2007. View at Publisher · View at Google Scholar · View at PubMed
  129. S. Hu-Lieskovan, J. D. Heidel, D. W. Bartlett, M. E. Davis, and T. J. Triche, “Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma,” Cancer Research, vol. 65, no. 19, pp. 8984–8992, 2005. View at Publisher · View at Google Scholar · View at PubMed
  130. G. Lambert, J. R. Bertrand, E. Fattal et al., “EWS Fli-1 antisense nanocapsules inhibits Ewing sarcoma-related tumor in mice,” Biochemical and Biophysical Research Communications, vol. 279, no. 2, pp. 401–406, 2000. View at Publisher · View at Google Scholar · View at PubMed
  131. H. Elhamess, J. R. Bertrand, J. MacCario, A. Maksimenko, and C. Malvy, “Antitumor vectorized oligonucleotides in a model of ewing sarcoma: unexpected role of nanoparticles,” Oligonucleotides, vol. 19, no. 3, pp. 255–264, 2009. View at Publisher · View at Google Scholar · View at PubMed
  132. N. Toub, J. R. Bertrand, C. Malvy, E. Fattal, and P. Couvreur, “Antisense oligonucleotide nanocapsules efficiently inhibit EWS-Fli1 expression in a Ewing's sarcoma model,” Oligonucleotides, vol. 16, no. 2, pp. 158–168, 2006. View at Publisher · View at Google Scholar · View at PubMed
  133. S. Mateo-Lozano, P. C. Gokhale, V. A. Soldatenkov, A. Dritschilo, O. M. Tirado, and V. Notario, “Combined transcriptional and translational targeting of EWS/FLI-1 in Ewing's sarcoma,” Clinical Cancer Research, vol. 12, no. 22, pp. 6781–6790, 2006. View at Publisher · View at Google Scholar · View at PubMed
  134. D. Grimm, K. L. Streetz, C. L. Jopling et al., “Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways,” Nature, vol. 441, no. 7092, pp. 537–541, 2006. View at Publisher · View at Google Scholar · View at PubMed
  135. O. Awad, J. T. Yustein, P. Shah et al., “High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-Fli1 inhibition,” PLoS One, vol. 5, no. 11, Article ID e13943, 2010. View at Publisher · View at Google Scholar · View at PubMed
  136. S. Rahim, E. M. Beauchamp, Y. Kong, M. L. Brown, J. A. Toretsky, and A. Üren, “YK-4-279 inhibits ERG and ETV1 mediated prostate cancer cell invasion,” PLoS One, vol. 6, no. 4, 2011. View at Publisher · View at Google Scholar · View at PubMed
  137. W. R. Wilson and M. P. Hay, “Targeting hypoxia in cancer therapy,” Nature Reviews Cancer, vol. 11, no. 6, pp. 393–410, 2011. View at Publisher · View at Google Scholar · View at PubMed
  138. R. G. Maki, A. S. Kraft, K. Scheu et al., “A multicenter phase II study of bortezomib in recurrent or metastatic sarcomas,” Cancer, vol. 103, no. 7, pp. 1431–1438, 2005. View at Publisher · View at Google Scholar · View at PubMed
  139. T. Nakamura, K. Tanaka, T. Matsunobu et al., “The mechanism of cross-resistance to proteasome inhibitor bortezomib and overcoming resistance in Ewing's family tumor cells,” International Journal of Oncology, vol. 31, no. 4, pp. 803–811, 2007. View at Google Scholar
  140. A. Abudu, D. C. Mangham, G. M. Reynolds et al., “Overexpression of p53 protein in primary Ewing's sarcoma of bone: relationship to tumour stage, response and prognosis,” British Journal of Cancer, vol. 79, no. 7-8, pp. 1185–1189, 1999. View at Publisher · View at Google Scholar · View at PubMed
  141. H. Y. Huang, P. B. Illei, Z. Zhao et al., “Ewing sarcomas with p53 mutation or p16/p14ARF homozygous deletion: a highly lethal subset associated with poor chemoresponse,” Journal of Clinical Oncology, vol. 23, no. 3, pp. 548–558, 2005. View at Publisher · View at Google Scholar · View at PubMed
  142. L. Dauphinot, C. De Oliveira, T. Melot et al., “Analysis of the expression of cell cycle regulators in Ewing cell lines: EWS-FLI-1 modulates p57KIP2 and c-Myc expression,” Oncogene, vol. 20, no. 25, pp. 3258–3265, 2001. View at Publisher · View at Google Scholar · View at PubMed
  143. J. Joo, L. Christensen, K. Warner et al., “GLI1 is a central mediator of EWS/FLI1 signaling in Ewing Tumors,” PLoS One, vol. 4, no. 10, Article ID e7608, 2009. View at Publisher · View at Google Scholar · View at PubMed
  144. O. M. Tirado, S. Mateo-Lozano, J. Villar et al., “Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells,” Cancer Research, vol. 66, no. 20, pp. 9937–9947, 2006. View at Publisher · View at Google Scholar · View at PubMed
  145. C. Siligan, J. Ban, R. Bachmaier et al., “EWS-FLI1 target genes recovered from Ewing's sarcoma chromatin,” Oncogene, vol. 24, no. 15, pp. 2512–2524, 2005. View at Publisher · View at Google Scholar · View at PubMed